Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01239004 · ClinicalTrials.gov registry record · Phase 4
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A Phase 4 study of Dyslipidemia and Hyperglycemia, sponsored by Radiant Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 4
- Study locations
NCT01239004 is a Phase 4 study of Dyslipidemia and Hyperglycemia that has completed, run by Radiant Research. The registered enrollment target is 140 participants, below the 360-participant average among 40 other Dyslipidemia trials with a reported enrollment target (61% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01239004, a Phase 4 study of Dyslipidemia and Hyperglycemia, has completed, sponsored by Radiant Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 4
- Study locations
Study Summary
The present study will assess the low-density lipoprotein cholesterol (LDL-C) lowering effect of colesevelam as an adjunct to niacin for the improvement of lipids and glycemic control in dyslipidemic subjects with impaired fasting glucose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Colesevelam
Study Locations (4)
Illinois
- Radiant Research - Chicago
Kansas
- - Kansas City
Minnesota
- - Minneapolis
Missouri
- - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01239004
The ClinicalTrials.gov registry entry for NCT01239004 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 360-participant average among 40 other Dyslipidemia trials with a reported enrollment target (61% lower). The listed sponsor is Radiant Research, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dyslipidemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01239004 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Kansas, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01239004 about?
NCT01239004 is a clinical study titled "Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy". The present study will assess the low-density lipoprotein cholesterol (LDL-C) lowering effect of colesevelam as an adjunct to niacin for the improvement of lipids and glycemic control in dyslipidemic subjects with impaired fasting glucose.
What is the current status of trial NCT01239004?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2010-11. Estimated completion is 2011-08.
What conditions does trial NCT01239004 study?
This clinical trial studies the following conditions: Dyslipidemia, Hyperglycemia, Hyperlipidemia.
What interventions are being tested in trial NCT01239004?
The interventions under investigation include: Placebo (DRUG), Colesevelam (DRUG).
Who is sponsoring clinical trial NCT01239004?
This trial is sponsored by Radiant Research, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01239004 being conducted?
This trial has 4 study locations across Illinois, Kansas, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fluvastatin in Adults With Dislipidemia With History of Muscle Problems
COMPLETED · Phase 4
-
A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
COMPLETED · Phase 4
-
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
COMPLETED · Phase 4
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Cottonseed Oil Versus Matched PUFA Effects
RECRUITING · NA
-
Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.